European Union - Slovenian - EMA (European Medicines Agency)

mylan ireland limited - lenalidomid - multiple myeloma - imunosupresivi - multiple myelomalenalidomide mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. lenalidomide mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide mylan in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1-3a).

Slovenia - Slovenian - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

mylan s.a.s. - irinotekan - koncentrat za raztopino za infundiranje - irinotekan 17,33 mg / 1 ml - irinotekan

Slovenia - Slovenian - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

mylan s.a.s. - irinotekan - koncentrat za raztopino za infundiranje - irinotekan 17,33 mg / 1 ml - irinotekan

Slovenia - Slovenian - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

mylan s.a.s. - irinotekan - koncentrat za raztopino za infundiranje - irinotekan 17,33 mg / 1 ml - irinotekan

Slovenia - Slovenian - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

mylan s.a.s. - irinotekan - koncentrat za raztopino za infundiranje - irinotekan 17,33 mg / 1 ml - irinotekan

Slovenia - Slovenian - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

mylan s.a.s. - bendamustinijev klorid - prašek za koncentrat za raztopino za infundiranje - bendamustinijev klorid 2,5 mg / 1 ml - bendamustin

European Union - Slovenian - EMA (European Medicines Agency)

mylan s.a.s - ritonavir - okužbe z virusom hiv - antivirusi za sistemsko uporabo - ritonavir je indiciran v kombinaciji z drugimi protiretrovirusnimi zdravili za zdravljenje okuženih s hiv 1 (odrasli in otroci, stari 2 leti in starejši).

European Union - Slovenian - EMA (European Medicines Agency)

mylan ireland limited - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.

European Union - Slovenian - EMA (European Medicines Agency)

mylan ireland limited - abirateron acetat - prostatične neoplazme - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Slovenia - Slovenian - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

mylan s.a.s. - paklitaksel - koncentrat za raztopino za infundiranje - paklitaksel 6 mg / 1 ml - paklitaksel